{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:27:30Z","timestamp":1766399250048},"reference-count":8,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1735,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1111\/j.1479-8301.2010.00338.x","type":"journal-article","created":{"date-parts":[[2010,12,15]],"date-time":"2010-12-15T14:18:31Z","timestamp":1292422711000},"page":"198-200","source":"Crossref","is-referenced-by-count":7,"title":["Five Alzheimer's disease cases with refractory behavioural psychological symptoms of dementia treated with blonanserin"],"prefix":"10.1111","volume":"10","author":[{"given":"Atsushi","family":"HAMURO","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satona","family":"SAITO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,12,15]]},"reference":[{"key":"10.1111\/j.1479-8301.2010.00338.x-BIB1|cit1","first-page":"461","article-title":"Preclinical characteristic and clinical positioning of blonanserin for schizophrenia","volume":"11","author":"Murasaki","year":"2008","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"10.1111\/j.1479-8301.2010.00338.x-BIB2|cit2","doi-asserted-by":"crossref","unstructured":"Amano N Inuzuka S Ogihara T Behavioral and psychological symptoms of dementia and medical treatment Psychogeriatrics 2009 9 45 49","DOI":"10.1111\/j.1479-8301.2009.00284.x"},{"key":"10.1111\/j.1479-8301.2010.00338.x-BIB3|cit3","first-page":"1451","article-title":"Assessment of functional changes in Alzheimer's disease","volume":"45","author":"Gauthier","year":"1990","journal-title":"Neuroepidemiology"},{"key":"10.1111\/j.1479-8301.2010.00338.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1017\/S0033291700032876","article-title":"A rating scale for aggressive behaviour in the elderly (the RAGE)","volume":"22","author":"Patel","year":"1992","journal-title":"Psychol Med"},{"key":"10.1111\/j.1479-8301.2010.00338.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1212\/WNL.34.7.939","article-title":"Clinical diagnosis of Alzheimer's: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease","volume":"34","author":"McKhann","year":"1984","journal-title":"Neurology"},{"key":"10.1111\/j.1479-8301.2010.00338.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of Risperidone and placebo for psychosis and behavioral disturbances associated with dementia; A randomized, double-blind trial-Risperidone Study Group","volume":"60","author":"Katz","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1111\/j.1479-8301.2010.00338.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trail-The HGEU Study Group","volume":"57","author":"Street","year":"2000","journal-title":"Arch Gen Psychiatry"},{"key":"10.1111\/j.1479-8301.2010.00338.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00002093-200204000-00011","article-title":"Cognitive and behavioral effects of quetiapine in Alzheimer disease patients","volume":"16","author":"Scharre","year":"2002","journal-title":"Alzheimer Dis Assoc Disord"}],"container-title":["Psychogeriatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1479-8301.2010.00338.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1479-8301.2010.00338.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T21:20:50Z","timestamp":1625520050000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1479-8301.2010.00338.x"}},"subtitle":["Blonanserin for the treatment of BPSD"],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,12]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1479-8301.2010.00338.x","relation":{},"ISSN":["1346-3500"],"issn-type":[{"value":"1346-3500","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]}}}